Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EPS (Weighted Average and Diluted) (2016 - 2025)

China Pharma Holdings filings provide 10 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.17 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 63.04% to -$0.17 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.74, a 72.79% increase, with the full-year FY2025 number at -$0.74, up 72.69% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.17 in Q4 2025 for China Pharma Holdings, roughly flat from -$0.17 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.02 in Q4 2023 to a low of -$0.89 in Q2 2024.
  • Median EPS (Weighted Average and Diluted) over the past 3 years was -$0.26 (2023), compared with a mean of -$0.38.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 2200.0% in 2024 and later surged 82.02% in 2025.
  • China Pharma Holdings' EPS (Weighted Average and Diluted) stood at -$0.02 in 2023, then crashed by 2200.0% to -$0.46 in 2024, then skyrocketed by 63.04% to -$0.17 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.17 (Q4 2025), -$0.17 (Q3 2025), and -$0.16 (Q2 2025) per Business Quant data.